Supernus Pharmaceuticals | SUPN - Loan Capital


Supernus Pharmaceuticals reported $400.38M in Loan Capital for its fiscal quarter ending in March of 2022.





Loan Capital Change Date
Abbott USD 9.9B 1.7B Dec/2025
ANI Pharmaceuticals USD 297.68M 310.67M Sep/2025
Aurora Cannabis CAD 34.99M 1.31M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Canopy Growth CAD 226.33M 62.67M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Eisai JPY 134.77B 12M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Pacira USD 376.72M 1.37M Sep/2025
Perrigo USD 3.61B 7.4M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
United Therapeutics USD 100M 100M Jun/2024
Xeris Pharmaceuticals USD 219.47M 839K Sep/2025